Your browser is no longer supported. Please, upgrade your browser.
GILD Gilead Sciences, Inc. daily Stock Chart
Gilead Sciences, Inc.
IndexS&P 500 P/E7.92 EPS (ttm)9.46 Insider Own0.40% Shs Outstand1.30B Perf Week2.10%
Market Cap97.50B Forward P/E9.93 EPS next Y7.55 Insider Trans-9.25% Shs Float1.30B Perf Month6.10%
Income12.64B PEG- EPS next Q2.15 Inst Own77.00% Short Float1.05% Perf Quarter9.30%
Sales29.10B P/S3.35 EPS this Y-16.50% Inst Trans0.13% Short Ratio1.59 Perf Half Y5.25%
Book/sh15.63 P/B4.80 EPS next Y-10.30% ROA22.80% Target Price76.70 Perf Year-8.35%
Cash/sh10.85 P/C6.91 EPS next 5Y-8.43% ROE70.50% 52W Range63.76 - 82.10 Perf YTD4.68%
Dividend2.08 P/FCF10.75 EPS past 5Y41.20% ROI31.00% 52W High-8.70% Beta1.22
Dividend %2.77% Quick Ratio2.40 Sales past 5Y29.40% Gross Margin86.20% 52W Low17.57% ATR1.32
Employees9000 Current Ratio2.60 Sales Q/Q-16.50% Oper. Margin57.60% RSI (14)76.25 Volatility1.69% 1.63%
OptionableYes Debt/Eq1.29 EPS Q/Q-18.90% Profit Margin43.40% Rel Volume1.61 Prev Close74.19
ShortableYes LT Debt/Eq1.29 EarningsJul 26 AMC Payout20.20% Avg Volume8.58M Price74.96
Recom2.50 SMA204.95% SMA5010.30% SMA2006.59% Volume13,842,407 Change1.04%
Jul-11-17Resumed Jefferies Hold
Jun-23-17Initiated Deutsche Bank Buy $79
Mar-09-17Resumed UBS Neutral $118 → $72
Feb-08-17Downgrade Citigroup Buy → Neutral
Nov-14-16Initiated Stifel Buy $100
Nov-08-16Initiated Mizuho Buy $88
Nov-02-16Reiterated RBC Capital Mkts Outperform $95 → $90
Oct-25-16Reiterated Jefferies Buy $93 → $95
Oct-03-16Reiterated RBC Capital Mkts Outperform $105 → $95
Sep-27-16Downgrade Leerink Partners Outperform → Mkt Perform $112 → $94
Sep-12-16Initiated Berenberg Buy $112
Sep-06-16Upgrade Jefferies Hold → Buy
Jul-29-16Downgrade Argus Buy → Hold
Jul-26-16Reiterated RBC Capital Mkts Outperform $120 → $105
Jul-26-16Downgrade Needham Buy → Hold
Jun-01-16Initiated Gabelli & Co Buy $109
Apr-29-16Reiterated UBS Buy $130 → $118
Apr-29-16Downgrade Maxim Group Buy → Hold
Mar-16-16Reiterated Leerink Partners Outperform $130 → $127
Feb-25-16Initiated Citigroup Buy $110
Jul-27-17 04:29PM  Biotech Fever Cools As These Players Dip On Longer-Term Views Investor's Business Daily
12:39PM  Biotechs Sell-Side Roundup: Cowens Take on Gilead Sciences, Inc. (GILD) and Celgene Corporation (CELG) SmarterAnalyst
10:07AM  Gilead Sciences, Inc. (GILD) Stock Has Tremendous Potential Even Post-Rally InvestorPlace
10:07AM  Gilead Sciences: The Biggest of Beats?
08:23AM  Early movers: CMCSA, TWTR, VZ, PG, LUV, DNKN & more CNBC
08:09AM  3 Stocks to Watch on Thursday: Buffalo Wild Wings (BWLD), Gilead Sciences, Inc. (GILD) and PayPal Holdings Inc (PYPL) InvestorPlace
08:06AM  J.P. Morgan Elevates Price Targets on Gilead Sciences, Inc. (GILD) and Vertex Pharmaceuticals Incorporated (VRTX) After Glowing 2Q Performance SmarterAnalyst
08:00AM  Gilead (GILD) Tops Q2 Earnings& Revenue Estimates, Stock Up Zacks
Jul-26-17 11:22PM  Edited Transcript of GILD earnings conference call or presentation 26-Jul-17 8:30pm GMT Thomson Reuters StreetEvents
09:30PM  Gilead beats Street 2Q forecasts Associated Press
07:30PM  Gilead Sciences Has 3 Available Options, but Only 1 Makes Sense Motley Fool
06:13PM  Gilead Sciences profit falls, but beats Wall Street estimates Reuters
06:06PM  Analysts Recommendations for Bristol-Myers Squibb in 2Q17 Market Realist
06:02PM  Gilead Sciences, Inc. Boosts Its Full-Year Outlook Thanks to Stronger-Than-Expected Hep C Sales Motley Fool
05:59PM  "Fast Money" final trades: GILD, UAL and more CNBC Videos
05:50PM  Gilead Still Doesn't Get a Deal Pass Bloomberg
05:22PM  Gilead (GILD) Shares Pop on Q2 Earnings and Revenue Beats Zacks
05:06PM  After-hours buzz: FB, PYPL, BWLD & more CNBC
05:00PM  Gilead's Hepatitis C Franchise Topples Again, But Shares Up On Beat Investor's Business Daily
05:00PM  Gilead surges after hours CNBC Videos
04:26PM  Gilead Sciences quarterly results beat Wall Street estimates Reuters
04:16PM  Gilead Sciences shares rise after quarterly results top Street view MarketWatch
04:04PM  Gilead Sciences beats the Street CNBC Videos
04:02PM  Gilead Sciences Announces Third Quarter 2017 Dividend Business Wire
04:01PM  Gilead Sciences Announces Second Quarter 2017 Financial Results Business Wire
09:35AM  Short Sellers Run for Cover From Major Biotech Stocks 24/7 Wall St.
09:35AM  Investor Network: Gilead Sciences, Inc. to Host Earnings Call Accesswire
06:00AM  Gilead Faces 6th Quarter of Falling Revenue Investopedia
Jul-25-17 05:30PM  Biotech still has more room to run: Technician CNBC Videos
02:31PM  What To Look For In Gilead Sciences, Inc. (GILD) Earnings SmarterAnalyst
11:18AM  Drug Stocks Q2 Earnings Releases on Jul 26: GILD, VRTX, GSK Zacks
08:30AM  Is a Surprise Coming for Gilead Sciences (GILD) This Earnings Season? Zacks
08:04AM  Gilead Sciences, Inc.s (GILD) Bictegravir Primed for Competition in HIV Market: Cowen SmarterAnalyst
07:19AM  3 Dividend Stocks That Thrive in Bear Markets Motley Fool
Jul-24-17 04:45PM  Gilead's HIV Drug Matches Glaxo Rival In Late-Stage Trials Investor's Business Daily
04:23PM  3 Things You Can Expect in Gilead Sciences' Q2 Update Motley Fool
03:17PM  Gilead Sciences: There's Always Safety
12:25PM  Gilead Sciences, Inc. (GILD) Stock Is a 2-for-1 Deal InvestorPlace
11:51AM  2 Ways To Trade This Week's Healthcare Earnings Benzinga
10:19AM  J.P. Morgan Comments on Gilead Sciences, Inc. (GILD) Following Clinical Results in HIV SmarterAnalyst
10:11AM  Surprise in Store for Healthcare in Q2: Buy Top-Ranked ETFs Zacks
07:35AM  Gilead Sciences says late-stage results for HIV drug combination are similar to standard of care MarketWatch
05:06AM  Gilead Announces Phase 3 Results for Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV Business Wire
04:00AM  HIV fight advances with new drug cocktails, fresh vaccine hopes Reuters
Jul-23-17 02:00PM  The Worm Has Turned in Biotech's Favor
Jul-22-17 11:43AM  Better Buy: Celgene Corporation vs. Gilead Sciences, Inc. Motley Fool
Jul-21-17 04:14PM  Biotechs On A Hot Streak, And Could Be 'Cooking With Gas' Investor's Business Daily
01:38PM  Will Gilead Beat 2Q Earnings? PerhapsBut Does It Matter?
11:23AM  What's in the Offing for Bristol-Myers (BMY) in Q2 Earnings? Zacks
07:37AM  Warren Buffett's Net Worth Would Be $100 Billion Right Now if Not for This Motley Fool
06:00AM  Better Buy: Valeant Pharmaceuticals International, Inc. vs. Gilead Sciences Motley Fool
Jul-20-17 02:00PM  Vertex Becomes an Overnight Biotech M&A Darling Bloomberg
08:49AM  Biotech Bulletin of the Week: Gilead Sciences, Inc. (GILD), Vertex Pharmaceuticals Incorporated (VRTX), and Keryx Biopharmaceuticals (KERX) SmarterAnalyst
08:30AM  Is Gilead (GILD) Poised for a Beat This Earnings Season? Zacks
Jul-19-17 04:26PM  How AbbVie Could Hammer Gilead's Hepatitis C Franchise Investor's Business Daily
02:51PM  Jefferies' Michael Yee: Still a valuation call in biotech CNBC Videos
10:19AM  Gilead Sciences: Not a Game Changer
10:15AM  Gilead's HCV Portfolio Receives a Boost With Vosevi Approval Zacks
08:03AM  When It Comes To Abusive Drug Pricing, Don't Confuse Shkreli With Hep C Drugs Forbes
Jul-18-17 04:15PM  Four Buffett-Inspired Picks That Could Outrun The Bulls Forbes
03:10PM  FDA approves Gilead's drug for chronic hep C patients Reuters
02:44PM  Gilead Secures FDA Approval For Chronic Hepatitis C Re-Treatment 24/7 Wall St.
01:35PM  U.S. Food and Drug Administration Approves Gileads Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir) for Re-Treatment of Adults with Chronic Hepatitis C Virus Business Wire
08:22AM  5 Big Pharma Stocks With the Best Drug Pipelines Motley Fool
08:18AM  5 Ways Gilead Sciences Could Spend Its Cash Hoard Motley Fool
06:00AM  Why Gilead Won't Buy Incyte and Vertex Investopedia
Jul-17-17 02:30PM  'Stars Align' For These Biotechs To Crush Earnings Consensus Investor's Business Daily
11:26AM  How Intangible Assets Create Value Market Realist
08:56AM  Health-care fund manager with 20% gain this year sees good times ahead as FDA becomes more accommodating MarketWatch
Jul-16-17 08:05PM  Will the Drug Pricing Executive Order Help Big Pharma? Motley Fool
11:01AM  These 3 Charts Don't Lie: Gilead Sciences Needs an Acquisition Motley Fool
Jul-15-17 04:00AM  Gilead (GILD) Application for HIV Drug Validated in EU Zacks
12:01AM  [$$] "A Great Time" to Invest in the Health-Care Sector
Jul-14-17 04:44PM  Gilead Could Acquire This Biotech But Vertex Is Still Better: Analyst Investor's Business Daily
02:37PM  Could Q2 Surprise Spike This Beleaguered Biotech's Stock? Investor's Business Daily
02:35PM  Gilead (GILD) Application for HIV Drug Validated in EU Zacks
09:30AM  The Zacks Analyst Blog Highlights: Merck, Celgene, Gilead Sciences, Seattle Genetics and Vanda Pharmaceuticals Zacks
Jul-13-17 02:31PM  5 Drug Stocks Well Poised to Beat Q2 Earnings Estimates Zacks
09:40AM  Short Sellers Hike Bets in Major Biotechs 24/7 Wall St.
09:30AM  The Zacks Analyst Blog Highlights: Merck, Eli Lilly, Celgene, Gilead Sciences and Shire Zacks
09:02AM  3 Dividend Stocks That Are Minting Money Motley Fool
08:20AM  3 Value Stocks for Discriminating Investors Motley Fool
08:13AM  5 Pharma & Biotech Stocks That Could Be Big Winners in Q2 Earnings Zacks
06:57AM  European Medicines Agency Validates Gileads Marketing Application for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV Business Wire
Jul-12-17 05:00PM  Gilead Sciences to Release Second Quarter 2017 Financial Results on Wednesday, July 26, 2017 Business Wire
04:17PM  Top 5 Biotech Stocks for 2017 Investopedia
Jul-11-17 10:23AM  3 Red-Hot Biotech Stocks That Could Get Even Hotter
Jul-10-17 04:05PM  A Look at Gilead Sciences Stock in 2Q17 Market Realist
02:19PM  Three Biotechs That Look Best Positioned Ahead Of Q2 Earnings
11:55AM  3 Dividend Stocks for Long-Term Investors Motley Fool
Jul-09-17 05:38PM  This $156 Billion Hedge Fund 'Hate List' Is Dead Wrong About These Stocks
11:01AM  How Shrewd of a Dealmaker Is Gilead Sciences? Just Look at Its Last 7 Acquisitions Motley Fool
Jul-07-17 06:37PM  What's Behind Gilead Sciences, Inc.'s 9.5% Rally in June Motley Fool
04:48PM  Are Gilead's Fortunes About To Change Without An Acquisition? Investor's Business Daily
07:48AM  Will Gilead's Dividend Keep Climbing? Motley Fool
Jul-05-17 04:57PM  Galapagos-Gilead Begin Phase II Study on Uveitis Candidate Zacks
10:20AM  Bank on Gilead Sciences, Inc. (GILD) Stock Getting Its Mojo Back InvestorPlace
09:00AM  Why Gilead Stock Is Back in the Game Investopedia
12:12AM  [$$] Better Ways to Measure Bosss Pay The Wall Street Journal
Jul-04-17 07:38AM  United Therapeutics Orenitram May Show Revenue Growth in 2017 Market Realist
Gilead Sciences, Inc. discovers, develops, and commercializes medicines in the areas of unmet medical needs in Europe, North America, Asia, South America, Africa, Australia, India, and the Middle East. The company's products include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis C virus and hepatitis B virus; hematology/oncology; cardiovascular; and inflammation/respiratory diseases. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., Galapagos NV., and Spring Bank Pharmaceuticals, Inc. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJul 21Option Exercise26.9934,500931,155137,488Jul 25 06:53 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJul 21Sale74.0040,0002,960,00097,488Jul 25 06:53 PM
MARTIN JOHN CExecutive ChairmanJul 03Option Exercise21.5873,3331,582,1593,199,969Jul 06 06:38 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJul 03Sale71.065,000355,295102,988Jul 06 06:27 PM
MARTIN JOHN CExecutive ChairmanJul 03Sale71.0073,3335,206,8923,126,636Jul 06 06:38 PM
MARTIN JOHN CExecutive ChairmanJun 01Option Exercise21.5873,3331,582,1593,273,302Jun 05 06:26 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJun 01Sale65.025,000325,114107,988Jun 05 06:15 PM
MARTIN JOHN CExecutive ChairmanJun 01Sale65.2473,3334,784,5313,199,969Jun 05 06:26 PM
Cogan John FrancisDirectorMay 09Option Exercise20.7115,000310,57562,562May 11 06:14 PM
Cogan John FrancisDirectorMay 09Sale67.259,943668,66752,619May 11 06:14 PM
MARTIN JOHN CExecutive ChairmanMay 01Option Exercise21.5873,3331,582,1593,199,969May 03 05:42 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffMay 01Sale68.315,000341,529112,988May 03 05:41 PM
MARTIN JOHN CExecutive ChairmanMay 01Sale68.3173,3335,009,4293,126,636May 03 05:42 PM
MARTIN JOHN CExecutive ChairmanApr 03Option Exercise21.5873,3331,582,1593,199,969Apr 05 05:29 PM
MARTIN JOHN CExecutive ChairmanApr 03Sale67.1873,3334,926,2873,126,636Apr 05 05:29 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffMar 30Sale67.485,000337,392117,988Apr 03 06:23 PM
MOORE NICHOLAS GDirectorMar 01Option Exercise0.00173012,055Mar 03 06:03 PM
MARTIN JOHN CExecutive ChairmanMar 01Option Exercise21.5873,3331,582,1593,199,969Mar 03 06:29 PM
MARTIN JOHN CExecutive ChairmanMar 01Sale70.3873,3335,161,2063,126,636Mar 03 06:29 PM
WILSON GAYLE EDirectorFeb 23Option Exercise20.7133,350690,512140,836Feb 27 06:29 PM
MILLIGAN JOHN FPresident and CEOFeb 23Option Exercise21.58100,0002,157,5001,165,924Feb 27 06:13 PM
WILSON GAYLE EDirectorFeb 23Sale69.3020,3651,411,374120,471Feb 27 06:29 PM
YOUNG KEVINChief Operating OfficerFeb 10Option Exercise0.0090802,883Feb 14 12:53 PM
MARTIN JOHN CExecutive ChairmanFeb 01Option Exercise21.5873,3331,582,1593,204,429Feb 03 05:25 PM
YOUNG KEVINChief Operating OfficerFeb 01Option Exercise0.0062002,190Feb 03 05:32 PM
MARTIN JOHN CExecutive ChairmanFeb 01Sale72.5773,3335,322,0693,131,096Feb 03 05:25 PM
MARTIN JOHN CExecutive ChairmanJan 03Option Exercise21.5873,3371,582,2463,204,433Jan 05 03:39 PM
MARTIN JOHN CExecutive ChairmanJan 03Sale73.5973,3375,396,9713,131,096Jan 05 03:39 PM
WILSON GAYLE EDirectorDec 01Option Exercise0.002,1470107,486Dec 05 07:59 PM
MARTIN JOHN CExecutive ChairmanDec 01Option Exercise16.40100,0001,639,5003,231,096Dec 05 12:54 PM
MARTIN JOHN CExecutive ChairmanDec 01Sale73.33100,0007,332,8703,131,096Dec 05 12:54 PM
MADIGAN JOHN WDirectorNov 18Option Exercise20.71105,0002,174,025121,761Nov 22 02:45 PM
MADIGAN JOHN WDirectorNov 18Sale74.86105,0007,860,05916,761Nov 22 02:45 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffNov 09Sale79.0010,000790,000122,964Nov 14 01:03 PM
MARTIN JOHN CExecutive ChairmanNov 01Option Exercise16.40100,0001,639,5003,231,096Nov 03 06:10 PM
MARTIN JOHN CExecutive ChairmanNov 01Sale73.76100,0007,376,0463,131,096Nov 03 06:10 PM
MARTIN JOHN CExecutive ChairmanOct 03Option Exercise16.40100,0001,639,5003,231,096Oct 05 12:52 PM
MARTIN JOHN CExecutive ChairmanOct 03Sale77.63100,0007,762,9613,131,096Oct 05 12:52 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffSep 22Sale81.845,000409,220132,964Sep 26 04:54 PM
MILLIGAN JOHN FPresident and CEOSep 06Option Exercise20.7470,0001,451,8001,128,963Sep 08 01:35 PM
MILLIGAN JOHN FPresident and CEOSep 06Sale77.7470,0005,442,0801,058,963Sep 08 01:35 PM
MARTIN JOHN CExecutive ChairmanSep 01Option Exercise16.40100,0001,639,5003,231,096Sep 06 02:40 PM
MARTIN JOHN CExecutive ChairmanSep 01Sale77.48100,0007,748,3633,131,096Sep 06 02:40 PM
Lofton Kevin EDirectorAug 24Sale81.973,500286,8990Aug 25 05:05 PM
Carter Paul RutherfordEVP Commercial OpsAug 01Option Exercise39.132,00078,25564,305Aug 03 04:48 PM
MARTIN JOHN CExecutive ChairmanAug 01Option Exercise16.40100,0001,639,5004,119,727Aug 03 04:51 PM
MILLIGAN JOHN FPresident and CEOAug 01Option Exercise20.7470,0001,451,8001,128,963Aug 03 04:53 PM
MILLIGAN JOHN FPresident and CEOAug 01Sale70.9470,0004,965,5901,058,963Aug 03 04:53 PM
MARTIN JOHN CExecutive ChairmanAug 01Sale80.50100,0008,049,7854,019,727Aug 03 04:51 PM
Carter Paul RutherfordEVP Commercial OpsAug 01Sale79.812,000159,62062,305Aug 03 04:48 PM
Carter Paul RutherfordEVP Commercial OpsJul 31Option Exercise0.002,500063,622Aug 02 04:43 PM